ERBB2 and triple-negative breast carcinoma: In the present study, most tumors (82.5%) were located at the lateral quadrant; the molecular subtype of Her2 negative (Hormone Receptor (HR)+), Her2 positive (HR+/−) and TNBC (triple negative breast cancer) are 30.7, 34.2, and 35.1% respectively; and the rate of tumor staging that under stage IIIA is 64.9% (Table 1).